- Home
- RXRX vs LGND Comparison
RXRX vs LGND Comparison
Compare RXRX & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RXRX
- LGND
- Stock Information
- Founded
- RXRX 2013
- LGND 1987
- Country
- RXRX United States
- LGND United States
- Employees
- RXRX N/A
- LGND N/A
- Industry
- RXRX Biotechnology: Pharmaceutical Preparations
- LGND Biotechnology: Pharmaceutical Preparations
- Sector
- RXRX Health Care
- LGND Health Care
- Exchange
- RXRX Nasdaq
- LGND Nasdaq
- Market Cap
- RXRX 2.0B
- LGND 2.0B
- IPO Year
- RXRX 2021
- LGND 1992
- Fundamental
- Price
- RXRX $6.18
- LGND $111.71
- Analyst Decision
- RXRX Buy
- LGND Strong Buy
- Analyst Count
- RXRX 6
- LGND 6
- Target Price
- RXRX $9.40
- LGND $144.83
- AVG Volume (30 Days)
- RXRX 5.5M
- LGND 142.9K
- Earning Date
- RXRX 11-06-2024
- LGND 11-07-2024
- Dividend Yield
- RXRX N/A
- LGND N/A
- EPS Growth
- RXRX N/A
- LGND 160.46
- EPS
- RXRX N/A
- LGND 2.47
- Revenue
- RXRX $65,184,000.00
- LGND $152,422,000.00
- Revenue This Year
- RXRX $50.69
- LGND $23.19
- Revenue Next Year
- RXRX $40.10
- LGND $15.08
- P/E Ratio
- RXRX N/A
- LGND $45.20
- Revenue Growth
- RXRX 37.64
- LGND N/A
- 52 Week Low
- RXRX $5.89
- LGND $57.00
- 52 Week High
- RXRX $15.74
- LGND $129.90
- Technical
- Relative Strength Index (RSI)
- RXRX 41.15
- LGND 48.80
- Support Level
- RXRX $6.68
- LGND $119.69
- Resistance Level
- RXRX $8.49
- LGND $125.76
- Average True Range (ATR)
- RXRX 0.51
- LGND 5.73
- MACD
- RXRX -0.02
- LGND -0.30
- Stochastic Oscillator
- RXRX 1.07
- LGND 25.51
About RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.